Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 2

Sponsor Class

NIH 2INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 3Gastrointestinal 2CNS 2Sarcoma 1

Conditions

Liver Neoplasms 2Carcinoma, Hepatocellular 2Liver Neoplasms, Experimental 1Adenoma, Liver Cell 1

Interventions

Fluorouracil 126Leucovorin 90Oxaliplatin 82Specimen Handling 71Gemcitabine 61Magnetic Resonance Spectroscopy 55Irinotecan 55Biopsy 53Capecitabine 40Bevacizumab 40Radiotherapy 37Cisplatin 34Cetuximab 29Chemotherapy, Adjuvant 28Erlotinib Hydrochloride 26Neoadjuvant Therapy 21dehydroftorafur 20Cyclophosphamide 19Nivolumab 18Sorafenib 17Radiation 17Paclitaxel 17X-Rays 16Doxorubicin 16aldesleukin 14Immunoglobulin G 14Disulfides 14fludarabine 13Folfox protocol 13Carboplatin 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × carotuximab × Gastrointestinal × Clear all
NCT01306058 2019-01-23

Sorafenib and TRC105 in Hepatocellular Cancer

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
27 enrolled 32 charts
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms, Liver Neoplasms, Experimental, Adenoma, Liver Cell

NCT01375569 2017-07-28

TRC105 for Liver Cancer That Has Not Responded to Sorafenib

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
11 enrolled 10 charts
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡